Search results for "monoclonal antibody"

showing 6 items of 356 documents

Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.

2015

Abstract: Introduction: The identification of cell membrane-bound molecules with a relevant role in cancer cell survival prompted the development of moAbs to block the related pathways. In the last few years, the number of approved moAbs for cancer treatment has constantly increased. Many of these drugs significantly improved the survival outcomes in patients with solid tumours. Areas covered: In this review, all the FDA-approved moAbs in solid tumours have been described. This is an update of moAbs available for cancer treatment nowadays in comparison with the moAbs approved until few years ago. The moAbs under development are also discussed here. Expert opinion: The research on cancer ant…

medicine.medical_treatmentClinical BiochemistryCellReceptor activator of nuclear factor κB ligandCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)NeoplasmsMonoclonalDrug DiscoveryDrug approvalCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all); Cancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)Drug ApprovalCancerbiologyMedicine (all)Antibodies MonoclonalVEGFReceptor activator of nuclear factor κB ligandmedicine.anatomical_structureMonoclonalMoAbsImmunotherapyAntibodyEngineering sciences. TechnologyHumanUnited StateCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)medicine.drug_classEGFRMonoclonal antibodyAntibodiesCancer antigenCytotoxic T-lymphocyte antigen 4HER2medicineHumansBiologyPharmacologybusiness.industryUnited States Food and Drug AdministrationDrug Discovery3003 Pharmaceutical ScienceCancerImmunotherapymedicine.diseaseUnited StatesImmunologyCancer cellCancer researchbiology.proteinNeoplasmMoAbHuman medicinebusinessExpert opinion on biological therapy
researchProduct

The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies.

2021

Since the approval of the first monoclonal antibody (mAb) in 1986, a huge effort has been made to guarantee safety and efficacy of therapeutic mAbs. As of July 2021, 118 mAbs are approved for the European market for a broad range of clinical indications. In order to ensure clinical efficacy and safety aspects, (pre-)clinical experimental approaches evaluate the respective modes of action (MoA). In addition to antigen-specificity including binding affinity and -avidity, MoA comprise Fc-mediated effector functions such as antibody dependent cellular cytotoxicity (ADCC) and the closely related antibody dependent cellular phagocytosis (ADCP). For this reason, a variety of cell-based assays have…

modes of action (MoA)GlycosylationQH301-705.5medicine.drug_classCellReceptors FcReviewBiologyMonoclonal antibodyCatalysisInorganic Chemistrychemistry.chemical_compoundMonoklonaler Antikörper ; effector function ; antibody dependent cellular phagocytosis (ADCP) ; therapeutic monoclonal antibodies (mAbs) ; Fcγ receptor (FcγR) ; modes of action (MoA) ; antibody dependent cellular cytotoxicity (ADCC)medicineAnimalsHumansAvidityClinical efficacyBiology (General)Physical and Theoretical ChemistryReceptorQD1-999Molecular BiologySpectroscopyAntibody-dependent cell-mediated cytotoxicityEffectortherapeutic monoclonal antibodies (mAbs)Organic ChemistryAntibody-Dependent Cell CytotoxicityAntibodies Monoclonalantibody dependent cellular phagocytosis (ADCP)General MedicineFcγ receptor (FcγR)Computer Science ApplicationsImmunoglobulin Fc Fragmentsantibody dependent cellular cytotoxicity (ADCC)Chemistrymedicine.anatomical_structurechemistryImmunologyImmunotherapyeffector functionInternational journal of molecular sciences
researchProduct

Trastuzumab-emtansine induced pleural and pericardial effusions

2021

Introduction Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate which combine trastuzumab (T), a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), and a cytotoxic molecule derived from maytansine (DM1). Case report We report the first case of T-DM1-associated pleural and pericardial effusions three weeks after the second course of T-DM1 in a patient with breast cancer. Drug-induced pleural and pericardial effusions was implicated in the absence of other etiologies. The Naranjo Scale indicated a probable drug-induced adverse reaction. Management & outcome: The patient fully recovered after thoracentesis and discontinuation of T-DM1. The patient h…

musculoskeletal diseasesReceptor ErbB-2medicine.drug_classBreast NeoplasmsAdo-Trastuzumab EmtansineAntibodies Monoclonal HumanizedMonoclonal antibodyPericardial effusionPericardial Effusion03 medical and health scienceschemistry.chemical_compound0302 clinical medicineTrastuzumabmedicineHumansMaytansinePharmacology (medical)business.industryHuman epidermal growth factorTrastuzumabmedicine.diseaseOncologychemistryTrastuzumab emtansine030220 oncology & carcinogenesisCancer researchFemalebusiness030215 immunologymedicine.drugConjugateJournal of Oncology Pharmacy Practice
researchProduct

Evidence for Positive Selection in the Capsid Protein-Coding Region of the Foot-and-Mouth Disease Virus (FMDV) Subjected to Experimental Passage Regi…

2001

We present sequence data from two genomic regions of foot-and-mouth disease virus (FMDV) subjected to several experimental passage regimens. Maximum-likelihood estimates of the nonsynonymous-to-synonymous rate ratio parameter (dN/dS) suggested the action of positive selection on some antigenic sites of the FMDV capsid during some experimental passages. These antigenic sites showed an accumulation of convergent amino acid replacements during massive serial cytolytic passages and also in persistent infections of FMDV in cell culture. This accumulation was most significant at the antigenic site A (the G-H loop of capsid VP1), which includes an Arg-Gly-Asp (RGD) cellular recognition motif. Our …

parallel evolutionmedicine.drug_class[SDV]Life Sciences [q-bio]virusesMolecular Sequence DataPopulationMonoclonal antibodyVirusEvolution Molecular03 medical and health sciencesAphthovirusCapsidAntigenpositive selectionGeneticsmedicineCoding regionSelection GeneticSerial Passageconvergent evolutioneducationMolecular BiologyPhylogenyEcology Evolution Behavior and Systematics030304 developmental biologychemistry.chemical_classification0303 health scienceseducation.field_of_studyModels GeneticbiologyFoot-and-mouth disease virusfoot-and-mouth disease virusexperimental phylogeny030306 microbiologyParallel evolutionbiochemical phenomena metabolism and nutritionbiology.organism_classificationVirology3. Good healthAmino acidPositive selection[SDV] Life Sciences [q-bio]CapsidchemistryFoot-and-mouth disease virusExperimental phylogenyConvergent evolutionMolecular Biology and Evolution
researchProduct

Photoluminescent Detection of Human T-Lymphoblastic Cells by ZnO Nanorods.

2020

The precise detection of cancer cells currently remains a global challenge. One-dimensional (1D) semiconductor nanostructures (e.g., ZnO nanorods) have attracted attention due to their potential use in cancer biosensors. In the current study, it was demonstrated that the possibility of a photoluminescent detection of human leukemic T-cells by using a zinc oxide nanorods (ZnO NRs) platform. Monoclonal antibodies (MABs) anti-CD5 against a cluster of differentiation (CD) proteins on the pathologic cell surface have been used as a bioselective layer on the ZnO surface. The optimal concentration of the protein anti-CD5 to form an effective bioselective layer on the ZnO NRs surface was selected. …

room temperature photoluminescenceT-LymphocytesPharmaceutical Science02 engineering and technologyBiosensing TechniquesT-lymphoblasts detection01 natural sciencesAnalytical Chemistryhemic and lymphatic diseasesDrug Discoveryeducation.field_of_studyNanotubesmedicine.diagnostic_testAntibodies MonoclonalPrecursor Cell Lymphoblastic Leukemia-Lymphoma021001 nanoscience & nanotechnologyFlow CytometryChemistry (miscellaneous)Molecular MedicineNanorodZinc Oxide0210 nano-technologymonoclonal antibody anti-CD5PhotoluminescenceMaterials sciencePopulationchemistry.chemical_elementNanotechnologyZincCD5 AntigensArticleFlow cytometrylcsh:QD241-441Adsorptionlcsh:Organic chemistryCell Line TumormedicineHumansPhysical and Theoretical ChemistryeducationMOLT-4 cell linecluster of differentiation proteins010401 analytical chemistryOrganic Chemistry0104 chemical sciencesNanostructureschemistryCancer cellLuminescent MeasurementsGlassBiosensorzinc oxide nanorodsMolecules (Basel, Switzerland)
researchProduct

Rapid and sensitive detection of metapneumovirus in clinical specimens by indirect fluorescence assay using a monoclonal antibody.

2008

Human metapneumovirus, with two known genotypes named A and B, is associated with mild respiratory symptoms to severe LRTI in children, high-risk adults and the elderly. Rapid and reliable methods of hMPV detection in clinical samples are essential to implement appropriate care, to better understand the pathology of hMPV and to determine its epidemiology. Respiratory samples from 1,386 patients collected during 2 consecutive years were screened for hMPV using indirect immunofluorescence (IFA) assay with a monoclonal antibody. Forty-three patients tested positive for hMPV by the IFA method. In parallel, the samples were examined with RT-PCR on the F gene. Of these, 41 specimens were RT-PCR p…

virusesMESH : AgedMESH : Respiratory Tract InfectionsMESH : Fluorescent Antibody Technique IndirectFusion geneMiceMESH : ChildGenotypeMetapneumovirusRespiratory systemChildFluorescent Antibody Technique IndirectAntigens ViralRespiratory Tract InfectionsCells CulturedComputingMilieux_MISCELLANEOUS[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/VirologyMice Inbred BALB CParamyxoviridae Infectionsmedicine.diagnostic_testbiologyAntibodies Monoclonalvirus diseasesMESH : AdultInfectious DiseasesMESH : Antibodies MonoclonalMESH : Sensitivity and SpecificityAdultmedicine.drug_classMonoclonal antibodyImmunofluorescenceSensitivity and Specificity[ SDV.MP.VIR ] Life Sciences [q-bio]/Microbiology and Parasitology/VirologyVirusHuman metapneumovirusVirologyMESH : MiceMESH : Cells CulturedmedicineAnimalsHumansMESH : Mice Inbred BALB CAgedMESH : HumansMESH : Antigens ViralMESH : Paramyxoviridae Infectionsbiology.organism_classificationVirologyrespiratory tract diseasesMESH : MetapneumovirusMetapneumovirusMESH : Animals
researchProduct